71
Nature Medicine, Published online: 07 January 2026; doi:10.1038/s41591-025-04101-y
In a multicenter, randomized trial of patients with atrial fibrillation and a low risk of thromboembolic events, treatment with the anticoagulant rivaroxaban showed no benefit in reducing cognitive decline, stroke or transient ischemic attack when compared to placebo.
